Tonix Pharmaceuticals Holding (TNXP) EBITDA (2011 - 2026)

Tonix Pharmaceuticals Holding's EBITDA history runs 16 years deep, the most recent figure standing at -$41.5 million for Q1 2026.

• On a quarterly basis, EBITDA fell 158.73% year-over-year to -$41.5 million in Q1 2026; TTM through Mar 2026 was -$151.2 million, a 15.05% decrease from a year earlier, with the FY2025 full-year figure at -$125.7 million, up 8.05% from the prior year.
• EBITDA advanced to -$41.5 million in Q1 2026 per TNXP's latest filing, from -$48.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$15.6 million in Q3 2024 and bottomed at -$77.3 million in Q2 2024.
• The 5-year median for EBITDA is -$28.3 million (2025), against an average of -$31.4 million.
• Across the five-year window, EBITDA tumbled 166.59% in 2024 and jumped 63.4% in 2025, its largest moves.
• Year by year, EBITDA stood at -$32.7 million in 2022, then increased by 16.5% to -$27.3 million in 2023, then increased by 17.74% to -$22.5 million in 2024, then plunged by 114.8% to -$48.3 million in 2025, then advanced by 13.98% to -$41.5 million in 2026.
• Per Business Quant, the three latest TNXP EBITDA figures stand at -$41.5 million (Q1 2026), -$48.3 million (Q4 2025), and -$33.1 million (Q3 2025).